Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPMT | P51580 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.42 |
| ▸ | GMNN | O75496 | 1/20 | 0.42 |
| ▸ | HTR3B | O95264 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | HTR3A | P46098 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.42 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | XBP1 | P17861 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30954400 | 0.85 | TPMT (0.40) | TPMTTSHRHTR3EGMNNHTR3B | |
| SCHEMBL28078656 | 0.85 | CYP3A4 (0.46) | TPMTTSHRHTR3EGMNNHTR3B | |
| SCHEMBL11041995 | 0.82 | TPMT (0.56) | TPMTTSHRHTR3EGMNNHTR3B | |
| SCHEMBL6672858 | 0.82 | TPMT (0.56) | TPMTTSHRHTR3EGMNNHTR3B | |
| SCHEMBL11223920 | 0.81 | CA12 (0.40) | HSD17B10MAPTALDH1A1GAAPOLB | |
| SCHEMBL6965570 | 0.80 | TPMT (0.54) | TPMTTSHRHTR3EGMNNHTR3B | |
| SCHEMBL588343 | 0.78 | ALDH1A1 (0.62) | TPMTTSHRHTR3EGMNNHTR3B | |
| SCHEMBL29236450 | 0.78 | TPMT (0.52) | TPMTTSHRHTR3EGMNNHTR3B | |
| SCHEMBL1259 | 0.78 | PARP1 (0.64) | TSHRALOX15KMT2AALDH1A1GAA | |
| SCHEMBL4370629 | 0.78 | PARP1 (0.64) | TSHRALOX15KMT2AALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4634196-A1 | PERACID PROMOTERS IN THE IRIDIUM-CATALYZED HYDROSILYLATION SYNTHESIS OF HALOALKYLORGANOSILANES | Momentive Performance Materials GmbH (DE) | 2025-10-22 | — | — | EP | disclosed |
| WO-2024126692-A1 | PERACID PROMOTERS IN THE IRIDIUM-CATALYZED HYDROSILYLATION SYNTHESIS OF HALOALKYLORGANOSILANES | MOMENTIVE PERFORMANCE MATERIALS GMBH (DE) | 2024-06-20 | — | — | WO | disclosed |
| EP-2057140-B1 | MORPHOLINO PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2012-08-08 | — | — | EP | disclosed |
| US-7750003-B2 | Compounds-943 | ASTRAZENECA AB (SE) | 2010-07-06 | — | — | US | disclosed |
| EP-2074118-A2 | TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | AstraZeneca AB (SE) | 2009-07-01 | — | — | EP | disclosed |
| EP-2057140-A1 | MORPHOLINO PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF PROLIFERATIVE DISORDERS | AstraZeneca AB (SE) | 2009-05-13 | — | — | EP | disclosed |
| US-20090018134-A1 | Compounds - 945 | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | US | disclosed |
| WO-2009007748-A2 | TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | WO | disclosed |
| US-20080171743-A1 | Transcutaneous immunostimulation | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| WO-2008023159-A1 | MORPHOLINO PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2008-02-28 | — | — | WO | disclosed |
| US-4175079-A | CYCLIZATION, FORMATION/C-N/, DEHYDRATION | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1979-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018134-A1 | Compounds - 945 | MTOR, PIK3CA, PIK3R5 | TPMT 1177/4885TSHR 4356/4885HTR3E 4335/4885 |
| US-20080171743-A1 | Transcutaneous immunostimulation | NFATC1, TLR9, MTOR | TPMT 447/4885TSHR 3657/4885HTR3E 4870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.